Back-to-back pivotal failures force Theravance to lay off 270 staffers, prune R&D focus
If it all went well, Q3 was supposed to be harvest time for Theravance.
Both of its lead drugs — the pan-JAK inhibitor izencitinib and blood …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
